
    
      To provide clinical information on rates of late and very late stent thrombosis after
      Endeavor Drug-eluting Stent (DES)placement in an all comers population with a broad range of
      bleeding and thrombosis risk. EDUCATE will further analyze the current practice of clinicians
      regarding temporary cessation of antiplatelet therapy and its association with clinical
      outcomes. In addition, patients included in this broad Endeavor registry will also be
      contributed to the DAPT native study population for analysis of 12 vs 30 months duration of
      dual antiplatelet therapy.
    
  